CA2220997A1 - Adenovirus vectors for gene therapy - Google Patents

Adenovirus vectors for gene therapy

Info

Publication number
CA2220997A1
CA2220997A1 CA002220997A CA2220997A CA2220997A1 CA 2220997 A1 CA2220997 A1 CA 2220997A1 CA 002220997 A CA002220997 A CA 002220997A CA 2220997 A CA2220997 A CA 2220997A CA 2220997 A1 CA2220997 A1 CA 2220997A1
Authority
CA
Canada
Prior art keywords
gene therapy
adenovirus vectors
useful
contain
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002220997A
Other languages
French (fr)
Other versions
CA2220997C (en
Inventor
Frank L. Graham
Martina Anton
Michael A. Rudnicki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advec Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2220997A1 publication Critical patent/CA2220997A1/en
Application granted granted Critical
Publication of CA2220997C publication Critical patent/CA2220997C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Abstract

This invention provides a method for making adenovirus cloning vectors which contain a recombinase target site that is useful for the insertion of selected foreign proteins.
CA002220997A 1995-06-07 1996-06-07 Adenovirus vectors for gene therapy Expired - Lifetime CA2220997C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/473,168 US5919676A (en) 1993-06-24 1995-06-07 Adenoviral vector system comprising Cre-loxP recombination
US08/473,168 1995-06-07
PCT/CA1996/000375 WO1996040955A1 (en) 1995-06-07 1996-06-07 Adenovirus vectors for gene therapy

Publications (2)

Publication Number Publication Date
CA2220997A1 true CA2220997A1 (en) 1996-12-19
CA2220997C CA2220997C (en) 2007-04-24

Family

ID=23878471

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002220997A Expired - Lifetime CA2220997C (en) 1995-06-07 1996-06-07 Adenovirus vectors for gene therapy

Country Status (8)

Country Link
US (2) US5919676A (en)
EP (1) EP0832267B1 (en)
JP (1) JP3492700B2 (en)
AT (1) ATE213022T1 (en)
AU (1) AU724161B2 (en)
CA (1) CA2220997C (en)
DE (1) DE69619110T2 (en)
WO (1) WO1996040955A1 (en)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US20020136708A1 (en) * 1993-06-24 2002-09-26 Graham Frank L. System for production of helper dependent adenovirus vectors based on use of endonucleases
US6730507B1 (en) 1993-06-24 2004-05-04 Merck & Co., Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
US20020146392A1 (en) * 1993-06-24 2002-10-10 Frank L. Graham Helper dependent adenovirus vectors based on site-specific recombinases
US7045347B2 (en) 1993-06-24 2006-05-16 Advec, Inc. Helper dependent adenovirus vectors based on integrase family site-specific recombinases
US6379943B1 (en) * 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
JP4216350B2 (en) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 Recombinant DNA viral vector for animal cell infection
US6143557A (en) * 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
US20060110798A1 (en) * 1995-06-07 2006-05-25 Graham Frank L Cells expressing recombinase useful for adenovirus vector production and control of gene expression
WO1996040724A1 (en) 1995-06-07 1996-12-19 Life Technologies, Inc. Recombinational cloning using engineered recombination sites
US6720140B1 (en) * 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US6964861B1 (en) 1998-11-13 2005-11-15 Invitrogen Corporation Enhanced in vitro recombinational cloning of using ribosomal proteins
SI1445322T2 (en) 1995-06-15 2012-10-30 Crucell Holland Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
FR2737501B1 (en) * 1995-07-31 1997-10-24 Transgene Sa NOVEL AUXILIARY VIRUSES FOR THE PREPARATION OF RECOMBINANT VIRAL VECTORS
DE19623203A1 (en) * 1995-11-24 1997-05-28 Max Planck Gesellschaft Virus vector for the transfer of stable episomes
US20060088938A1 (en) * 1995-12-15 2006-04-27 Mitchell Lloyd G Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20030027250A1 (en) * 1995-12-15 2003-02-06 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
AU1695197A (en) * 1996-01-05 1997-08-01 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors
WO1997032481A1 (en) * 1996-03-07 1997-09-12 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
US6630346B1 (en) * 1996-06-20 2003-10-07 Merck & Co., Inc. Gene therapy for obesity
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
GB2321642B8 (en) * 1996-10-01 2006-08-22 Geron Corp Human telomerase reverse transcriptase promoter
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US5994132A (en) * 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
US6743620B1 (en) 1996-12-16 2004-06-01 Eisai Co., Ltd. Method for preparing retrovirus vector for gene therapy
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US5851808A (en) * 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
CA2283253A1 (en) * 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US7622549B2 (en) * 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US7413864B2 (en) * 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US20050013825A1 (en) * 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
AU9319198A (en) 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
DE69836092T2 (en) 1997-10-24 2007-05-10 Invitrogen Corp., Carlsbad RECOMBINATORY CLONING USING NUCLEAR FACILITIES WITH RECOMBINATION CENTERS
US7351578B2 (en) * 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
CA2311642A1 (en) * 1997-11-25 1999-06-03 Princeton University Method for preparing adenovirus vectors, vectors so prepared, and uses thereof
DE19807265C2 (en) * 1998-02-20 2000-01-05 Centeon Pharma Gmbh Adenoviral transfer vector for the gene transport of a DNA sequence
US6337200B1 (en) * 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AU764686B2 (en) 1998-08-28 2003-08-28 Duke University Adenoviruses deleted in the IVa2, 100K, polymerase and/or preterminal protein sequences
US6303362B1 (en) 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
CA2360796A1 (en) * 1999-02-04 2000-08-10 Merck & Co., Inc. Improved helper dependent vector system for gene therapy
WO2000049166A2 (en) * 1999-02-18 2000-08-24 Merck & Co., Inc. Production of helper dependent adenovirus vectors based on use of endonucleases
DE60042969D1 (en) 1999-03-02 2009-10-29 Life Technologies Corp PREPARATIONS AND METHODS FOR USE IN RECOMBINATORY CLONING OF NUCLEIC ACIDS
AU765093B2 (en) 1999-03-05 2003-09-11 Advec, Inc. Enhanced system for construction of adenovirus vectors
US20030215423A1 (en) * 1999-04-01 2003-11-20 Merck & Co., Inc. Gene therapy for obesity
JP2003519464A (en) * 1999-04-06 2003-06-24 メルク アンド カンパニー インコーポレイテッド Use of alternative serotype helper-dependent adenovirus vectors allows for repeated vector administration
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
DE122008000058I1 (en) * 1999-04-06 2009-05-07 Wisconsin Alumni Res Found RECOMBINANT INFLUENZA VIRUSES FOR VACCINATION AND GENE THERAPY
US8017590B1 (en) 1999-10-22 2011-09-13 Sanofi Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
ATE391789T1 (en) 1999-12-10 2008-04-15 Invitrogen Corp USE OF A VARIETY OF RECOMBINATION SITE WITH UNIQUE SPECIFICITY IN RECOMBINATORY CLONING
US6867022B1 (en) * 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
US7132277B1 (en) * 2000-01-31 2006-11-07 Merck & Co., Inc. Helper dependent vector system for gene therapy
CA2406180C (en) 2000-04-14 2013-05-28 Wisconsin Alumni Research Foundation Viruses comprising mutant ion channel protein
EP1282702B1 (en) 2000-05-10 2006-11-29 Sanofi Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
US7244560B2 (en) * 2000-05-21 2007-07-17 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
WO2002006451A1 (en) * 2000-07-18 2002-01-24 Uab Research Foundation Tissue-specific self-inactivating gene therapy vector
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
EP1317560A4 (en) * 2000-09-08 2005-10-05 Gen Hospital Corp Self-rearranging dna vectors
EP1320620B1 (en) 2000-09-25 2015-01-21 The Regents Of The University Of Michigan Production of viral vectors
JPWO2002041922A1 (en) * 2000-11-24 2004-03-25 丸山　弘樹 Method for controlling the activity of an expression product of a gene introduced into a living body
US20040126774A1 (en) * 2001-01-08 2004-07-01 Mitchell Lioyd G. Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
JP2004532039A (en) * 2001-03-26 2004-10-21 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ Helper-dependent adenovirus vector system and methods of using the system
JP2004531259A (en) * 2001-04-19 2004-10-14 インヴィトロジェン コーポレーション Compositions and methods for recombinant cloning of nucleic acid molecules
CA2448505A1 (en) * 2001-05-21 2002-11-28 Invitrogen Corporation Compositions and methods for use in isolation of nucleic acid molecules
EP1402020A2 (en) * 2001-06-28 2004-03-31 Phenogene Therapeutiques Inc. Methods, vectors, cell lines and kits for selecting nucleic acids having a desired feature
EP1427816A4 (en) * 2001-09-18 2004-12-01 Clontech Lab Inc Site-specific recombinase based method for producing adenoviral vectors
WO2003062400A2 (en) * 2002-01-24 2003-07-31 The Scripps Research Institute Fiber shaft modifications for efficient targeting
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
DE60315628T2 (en) 2002-04-09 2008-06-05 Sanofi Pasteur Ltd., Toronto MODIFIED CEA NUCLEIC ACID AND EXPRESSION VECTORS
EP1504016A4 (en) * 2002-05-08 2006-11-22 Intronn Inc Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses
US8304233B2 (en) 2002-06-04 2012-11-06 Poetic Genetics, Llc Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same
NZ539647A (en) * 2002-09-27 2007-05-31 Powderject Res Ltd Nucleic acid constructs for gene expression in eliciting an immune response
JP4654033B2 (en) * 2002-10-23 2011-03-16 バークシス コーポレーション Screening method for efficient pre-trans-splicing molecule identification
US20040203133A1 (en) * 2003-01-07 2004-10-14 Anja Ehrhardt Helper dependent adenoviral vector system and methods for using the same
EP1618191A2 (en) 2003-04-23 2006-01-25 Wisconsin Alumni Research Foundation Recombinant influenza viruses holding a mutation in a transmembrane protein gene
US20050095615A1 (en) * 2003-06-26 2005-05-05 Welch Peter J. Methods and compositions for detecting promoter activity and expressing fusion proteins
CN101124327A (en) * 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 Modified CEA/B7 vector
EP1697534B1 (en) 2003-12-01 2010-06-02 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
CA2553828A1 (en) * 2004-01-23 2005-08-04 Intronn, Inc. Expression of apoa-1 and variants thereof using spliceosome mediated rna trans-splicing
WO2005070948A1 (en) * 2004-01-23 2005-08-04 Intronn, Inc. Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
US20060094110A1 (en) * 2004-07-30 2006-05-04 Mcgarrity Gerard J Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
EP1804835B9 (en) 2004-09-13 2012-05-02 Genzyme Corporation Multimeric constructs
DE102004047492B4 (en) * 2004-09-23 2006-07-20 Jost-Werke Gmbh & Co. Kg Method for transmitting electrical, pneumatic or hydraulic energy and a power transmission system
US7871795B2 (en) 2004-10-08 2011-01-18 Virxsys Corporation Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
US7879321B2 (en) * 2004-10-08 2011-02-01 Virxsys Corporation Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
WO2007044024A2 (en) 2004-11-19 2007-04-19 Wisconsin Alumni Research Foundation Recombinant influenza vectors with tandem transcription units
WO2007110695A2 (en) * 2005-10-13 2007-10-04 Bc Cancer Agency Modular genomes for synthetic biology and metabolic engineering
AR059089A1 (en) 2006-01-20 2008-03-12 Genzyme Corp INTRAVENTRICULAR ADMINISTRATION OF AN ENZYME FOR LISOSOMAL STORAGE DISEASES
WO2007095056A2 (en) 2006-02-09 2007-08-23 Genzyme Corporation Slow intraventricular delivery
CN101472941B (en) 2006-03-31 2017-08-08 沃弗-威斯康星校友研究基金会 High titer recombinant influenza viruses for vaccine
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
ES2337973B8 (en) * 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. ADENOVIRUS AUXILIARY SELF-INACTIVANTS FOR THE PRODUCTION OF ADENOVIRUS RECOMBINANTS OF HIGH CAPACITY.
US9109013B2 (en) 2009-10-26 2015-08-18 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EA033803B1 (en) 2012-02-07 2019-11-27 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery, compositions and uses thereof
EP3022296B1 (en) 2013-07-15 2022-12-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
MX2016001667A (en) 2013-08-08 2016-11-07 Global Bio Therapeutics Inc Clamp device for minimally invasive procedures and uses thereof.
ES2739288T3 (en) 2013-09-13 2020-01-30 California Inst Of Techn Selective recovery
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
MX2018006840A (en) 2015-12-11 2019-03-28 California Inst Of Techn TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs).
JP2019510481A (en) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション Improved influenza B virus replication for vaccine development
CA3060573A1 (en) 2017-04-21 2018-10-25 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy
WO2020068990A1 (en) 2018-09-26 2020-04-02 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
JP2022551805A (en) 2019-08-27 2022-12-14 ウィスコンシン アルムニ リサーチ ファンデイション Recombinant Influenza Virus with Stabilized HA for Intraovo Replication
CN114787345A (en) * 2019-10-23 2022-07-22 吉恩迈生物科技有限公司 Helper plasmid-based enteroadenovirus-free production system
CA3171935A1 (en) 2020-03-15 2021-09-23 Mahmoud ELJENDY Recombinant protein production in insects
WO2023017494A1 (en) 2021-08-13 2023-02-16 Triovance Holding Llc A skin substitute composition and methods of producing and using the same
CN114410683B (en) * 2022-01-12 2023-11-28 中国人民解放军空军军医大学 RIM3-RNAi based on Cre-lox recombination system and application thereof
CN114369623B (en) * 2022-01-12 2023-07-07 中国人民解放军空军军医大学 Syntagmin 2-RNAi based on Cre-lox recombination system and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4920211A (en) * 1988-01-04 1990-04-24 Vanderbilt University Mutated adenovirus E1A gene for E1A promoter stimulation
FR2681786A1 (en) * 1991-09-27 1993-04-02 Centre Nat Rech Scient RECOMBINANT VECTORS OF VIRAL ORIGIN, PROCESS FOR OBTAINING SAME AND THEIR USE FOR THE EXPRESSION OF POLYPEPTIDES IN MUSCLE CELLS.
FR2688514A1 (en) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
AU1648092A (en) * 1992-03-19 1993-10-21 Cancer Research Campaign Technology Limited Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins
ATE404683T1 (en) * 1992-09-25 2008-08-15 Aventis Pharma Sa ADENOVIRUS VECTORS FOR TRANSFER OF FOREIGN GENES INTO CELLS OF THE CENTRAL NERVOUS SYSTEM, ESPECIALLY IN THE BRAIN
CA2166118C (en) * 1993-06-24 2007-04-17 Frank L. Graham Adenovirus vectors for gene therapy
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
JP4216350B2 (en) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 Recombinant DNA viral vector for animal cell infection

Also Published As

Publication number Publication date
AU724161B2 (en) 2000-09-14
EP0832267A1 (en) 1998-04-01
JP3492700B2 (en) 2004-02-03
WO1996040955A1 (en) 1996-12-19
AU5889796A (en) 1996-12-30
US20010041173A1 (en) 2001-11-15
JPH11506334A (en) 1999-06-08
CA2220997C (en) 2007-04-24
ATE213022T1 (en) 2002-02-15
EP0832267B1 (en) 2002-02-06
DE69619110T2 (en) 2002-07-18
US5919676A (en) 1999-07-06
DE69619110D1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
CA2220997A1 (en) Adenovirus vectors for gene therapy
AU6124996A (en) Certain arylsulfonamido-substituted hydroxamic acids for the treatment of certain tumors
AU5528296A (en) Yoke connections for universal joints
AU4209197A (en) Process for the control of weeds
AU7678196A (en) Methods and compositions for the delivery of monomeric proteins
AU699706C (en) Improved vectors for gene therapy
AU1348795A (en) Target practice apparatus
EP0637630A3 (en) Method for the biological synthesis of peptides
AU4835296A (en) Method for the secure updating of an eeprom memory
AU6844696A (en) Recombinant clone selection system
AU5289596A (en) Peptide suppressing ixbalpha phosphorylation
AU5799200A (en) Lpl variant therapeutics
AU2377095A (en) Apparatus for the manufacture of innerspring constructions
AU4087396A (en) Novel vectors and use thereof for capturing target genes
AU4792396A (en) Process for the preparation of ethyl-N-(2,3 dichloro-6- nitrobenzyl) glycine
CA2284142A1 (en) Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
AU4401297A (en) Improved retroviral vectors for gene therapy
EP1609864A3 (en) Use of neuronal apoptosis inhibitor protein (NAIP)
AU2540297A (en) Methods for enriching target nucleic acid sequences
WO1997008934A3 (en) Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
GB9725618D0 (en) Target tracking missile guidance method
PL333187A1 (en) Method of detecting compounds which modulate the performance of protein of obesity (ob)
IL133782A0 (en) Novel stereoselective processes for the preparation of gabapentin analogues
EP0756821A3 (en) Para-hydroxyphenylacetic acid for veducing the repellency of insecticides
WO2000029564A3 (en) Human glycine transporter type 2

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160607